Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer.

Pharmaceuticals (Basel) · 2023 · PMC9961924 · PMID 37259367

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Preliminary findings of a study in NSCLC with underlying idiopathic pulmonary fibrosis showed a trend of non-statistically significant better OS compared to X-rays for patients treated with PT [ 179 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.